Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL
Authors: Stephen D. Smith, Ajay K. Gopal
Journal: Journal of Clinical Oncology (2021)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. March 08, 2021 ARTICLE CITATION DOI: 10.1200/JCO.21.00284 Journal of Clinical Oncology - published online before print April 16, 2021 PMID: 33861621 Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL Stephen D. Smith , MD1,2,3xStephen D. SmithSearch for articles by this author and Ajay K. Gopal , MD1,2,3xAjay K. GopalSearch for articles by this author Show More 1Division of Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, WA2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA3Seattle Cancer Care Alliance, Seattle, WA https://doi.org/10.1200/JCO.21.00284 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: Ajay K. GopalData analysis and interpretation: Ajay K. GopalManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTUmbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHLThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Stephen D. SmithConsulting or Advisory Role: AstraZeneca, Takeda, Beige, Karyopharm Therapeutics, Kite, a Gilead company, Incyte, ADC TherapeuticsResearch Funding: Acerta Pharma/AstraZeneca, Bayer, Ayala Pharmaceuticals, Bristol-Myers Squibb, Denovo Biopharma, Genentech, Ignyta, Incyte, Merck, Pharmacyclics, Portola PharmaceuticalsAjay K. GopalHonoraria: Seattle Genetics, Pfizer, Gilead Sciences, Janssen Oncology, ADC Therapeutics, Amgen, I-Mab, Actinium Pharmaceuticals, Cellectar, Nurix, Takeda, Morphosys, Kite/Gilead, Epizyme, TG Therapeutics, MerckConsulting or Advisory Role: Pfizer, Seattle Genetics, Janssen Oncology, Millennium, Gilead Sciences, Nurix, Cellectar, Kite/Gilead, Morphosys, Incyte, I-Mab, TG TherapeuticsResearch Funding: Merck, Bristol-Myers Squibb, Gilead Sciences, Seattle Genetics, Teva, Pfizer, Janssen Oncology, Millennium, IgM Biosciences, I-Mab, Takeda, AstraZenecaNo other potential conflicts of interest were reported. Companion Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma